A system and method for pumping fluid through an organ donors organs while monitoring the fluid and organs. A pump is configured to pump fluid from a fluid reservoir through an oxygenator that oxygenates the fluid, a heat exchanger that regulates the temperature of the fluid, and into an organ donors circulatory system or a severed organ. At least one sensor array is coupled to the system to monitor the fluid and organ/s. The fluid pumped through the system is blood or flushing fluid, and the two can be used one at a time. The information gathered by the at least one sensor array is used to inform the system to make changes to increase the organ's likelihood of successful transplant.

A method of removing senescent cells from donor tissues or cells, organs, or autologous cells or tissues forms a tissue graft. The method comprises adding at least one senolytic therapy to the tissue or cells during processing or prior to storage. The senolytic therapy preferably involves any strategy to reduce senescent cells, reduce senescence phenotype, reduce factors that can cause senescent cells, target known senescence signaling (e.g. inhibitors or RNA therapeutics). The viable tissue graft comprises live tissue with enhanced biological properties. The amount of senescent cells in the graft is reduced by at least 15% as compared to an amount of senescent cells present in normal tissue. The amount of senescence-associated secretory phenotype SASPs in the graft is reduced by at least 10% as compared to an amount of senescence-associated secretory phenotype SASPs present in normal cells.

A method of removing senescent cells from donor tissues or cells, organs, or autologous cells or tissues forms a tissue graft. The method comprises adding at least one senolytic therapy to the tissue or cells during processing or prior to storage. The senolytic therapy preferably involves any strategy to reduce senescent cells, reduce senescence phenotype, reduce factors that can cause senescent cells, target known senescence signaling (e.g. inhibitors or RNA therapeutics). The viable tissue graft comprises live tissue with enhanced biological properties. The amount of senescent cells in the graft is reduced by at least 15% as compared to an amount of senescent cells present in normal tissue. The amount of senescence-associated secretory phenotype SASPs in the graft is reduced by at least 10% as compared to an amount of senescence-associated secretory phenotype SASPs present in normal cells.

Provided herein are formulations and methods for the stabilization of one or more thrombocytes at ambient temperatures. Also provided are formulations and methods for the stabilization of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures. Further provided are articles of manufacture and kits and methods for substantially stable storage of one or more thrombocyte at ambient temperatures.

Provided herein are formulations and methods for the stabilization of one or more thrombocytes at ambient temperatures. Also provided are formulations and methods for the stabilization of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures. Further provided are articles of manufacture and kits and methods for substantially stable storage of one or more thrombocyte at ambient temperatures.

Methods and systems of maintaining, evaluating, and providing therapy to a lung ex vivo. The methods and systems involve positioning the lung in an ex vivo perfusion circuit; circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface; and ventilating the lung by flowing a ventilation gas through a tracheal interface. Maintaining the lung for extended periods involves causing the lung to rebreath a captive volume of air, and reaching an equilibrium state between the perfusion fluid and the ventilation gas. Evaluating the gas exchange capability of the lung involves deoxygenating the perfusion fluid and measuring a time taken to reoxygenate the perfusion fluid by ventilating the lung with an oxygenation gas.

Methods and systems of maintaining, evaluating, and providing therapy to a lung ex vivo. The methods and systems involve positioning the lung in an ex vivo perfusion circuit; circulating a perfusion fluid through the lung, the fluid entering the lung through a pulmonary artery interface and leaving the lung through a left atrial interface; and ventilating the lung by flowing a ventilation gas through a tracheal interface. Maintaining the lung for extended periods involves causing the lung to rebreath a captive volume of air, and reaching an equilibrium state between the perfusion fluid and the ventilation gas. Evaluating the gas exchange capability of the lung involves deoxygenating the perfusion fluid and measuring a time taken to reoxygenate the perfusion fluid by ventilating the lung with an oxygenation gas.

A biological sample preservative contains 1.0 to 10.0 mol/L of a substance having a polyatomic monovalent cation represented by a chemical formula NH4.sup.+ or a compound comprising the polyatomic monovalent cation. As the substance having the polyatomic monovalent cation represented by the chemical formula NH4.sup.+ or the compound comprising the polyatomic monovalent cation, for example, ammonium sulfate or ammonium nitrate can be used.

A biological sample preservative contains 1.0 to 10.0 mol/L of a substance having a polyatomic monovalent cation represented by a chemical formula NH4.sup.+ or a compound comprising the polyatomic monovalent cation. As the substance having the polyatomic monovalent cation represented by the chemical formula NH4.sup.+ or the compound comprising the polyatomic monovalent cation, for example, ammonium sulfate or ammonium nitrate can be used.

The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.